Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Guideline-Endorsed Answers to Key Questions in Nontuberculous Mycobacterial Lung Disease Management
  • CME

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: November 19, 2021 Expiration: November 18, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Insmed Incorporated
Keira A. Cohen, MD
Program Director
person default
David E. Griffith, MD
Princy N. Kumar, MD, FIDSA, MACP

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Utilize appropriate clinical, radiographic, and microbiologic criteria for reducing time to NTM-LD diagnosis and characterization
  • Develop guideline-recommended and evidence-based approaches to the treatment of NTM-LD
  • Identify key issues of importance to patients surrounding their illness symptoms and treatment adverse events
  • In partnership with patients, provide individualized and comprehensive treatment plans for NTM-LD

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Keira A. Cohen, MD

Assistant Professor of Medicine
Pulmonary and Critical Care Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Keira A. Cohen, MD, has disclosed that she has received consulting fees from HillRom, Insmed, and Microbion and fees for non-CME/CE services from Insmed.

Faculty

David E. Griffith, MD

Professor of Medicine
Division of Mycobacterial and Respiratory Infections
Department of Medicine
National Jewish Hospital
Denver, Colorado

David E. Griffith, MD, has disclosed that he has received funds for research support from Insmed, consulting fees from AN2 Therapeutics and Insmed, and fees for non-CME/CE services from Insmed.
Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Chief,
Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has received funds for research support from Amgen, Gilead Sciences, GlaxoSmithKline, and Merck; has received consulting fees from Amgen, GlaxoSmithKline, and Merck; and has ownership interests in Gilead Sciences, Johnson & Johnson, Merck, and Pfizer.

Staff

Sarah Anderson, PharmD
Scientific Director
Sarah L. Anderson, PharmD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for infectious disease and pulmonology physicians, pharmacists, and other healthcare professionals who care for patients with NTM-LD.

Goal

The goal of this activity is to improve the knowledge and competence of learners to apply practice guidelines and provide patient-centered care in the diagnosis and management of NTM-LD.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-251-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 19, 2021, through November 18, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

How do you decide to start (or not start) treatment for NTM-LD?
  • CME

Loading...
Keira A. Cohen, MD
Program Director
person default
David E. Griffith, MD
Princy N. Kumar, MD, FIDSA, MACP
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: November 19, 2021 Expiration: November 18, 2022

Related Content

Clinical Care Options (CCO) commentary from Dr. Sahil Khanna regarding guideline changes for the diagnosis and treatment of C difficile infection

person default Sahil Khanna, MBBS, MS Released: January 21, 2022

Download slides reviewing the latest data and guidance on approaches to managing patients with hepatitis delta virus (HDV), from Clinical Care Options (CCO)

Maria Buti, MD Robert G. Gish, MD Released: January 21, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Dr Robert G. Gish: whom and how to test for hepatitis delta virus (HDV), from Clinical Care Options (CCO)

Robert G. Gish, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Released: January 18, 2022 Expired: January 17, 2023

Video Chapters


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Insmed Incorporated

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings